Carregant...
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
BACKGROUND: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic...
Guardat en:
| Publicat a: | Brain Behav |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6379644/ https://ncbi.nlm.nih.gov/pubmed/30656853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/brb3.1215 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|